[Acellular pertussis vaccines--safe alternative].
This study was undertaken to assess the safety of various acellular vaccines (ACV) TripAcel, PacMarieux--Pasteur Merieux, Infanrix-SKB, Acel-P-Lederle and DTaP-SSI in 355 children, aged 7 weeks to 7 years, dismissed from immunization against pertussis with a whole-cell vaccine. All ACV contained varying concentrations of pertussis toxin; some vaccines contained filamentous hemagglutinin, pertactin and/or agglutinogens. The indication of using ACV were adverse effects following immunization (AEFI) after wP vaccine (n = 29) and others reasons, mostly underlying perinatal and CNS pathology (n = 277). The 564 doses of ACV were given in 4 to 1 doses. Reaction forms and clinical follow-up were uniform throughout the study.


RESULTS
Serious AEFI cases were not observed not only among children with CNS damage, but also in children with previous AEFI after DTwP vaccine. All ACV recipients consistently reported low rates of reactions in the 48 hours following immunization. We concluded that all investigated ACV were safe and well tolerated even in the group of high-risk children.
Szenborn
L
L
Katedry i Kliniki Chorób Zakaźnych Dzieci AM we Wrocławiu.
Saraczyńska
E
E
D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010567:Pertussis Vaccine / Q000009:adverse effects*; D022282:Vaccines, Acellular
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D010567:Pertussis Vaccine; D022282:Vaccines, Acellular